Higher blood pressure in normal weight women with PCOS compared to controls

Mellembakken, Jan Roar; Mahmoudan, Azita; Mørkrid, Lars; Sundström‐Poromaa, Inger; Morin‐Papunen, Laure; Tapanainen, Juha S.; Piltonen, Terhi; Hirschberg, Angelica Lindén; Stener‐Victorin, Elisabet; Ravn, Pernille; Jensen, Richard Christian; Andersen, Marianne; Glintborg, Dorte

doi:10.1530/ec-20-0527

Cited by 19 publications

(10 citation statements)

References 45 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings were in accordance with that there is a close relationship between BMI and BP. The mechanism underlying the increased prevalence of hypertension in PCOS has been linked to several factors such as hyperinsulinemia, hyperandrogenemia, and obesity [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Metabolic and biochemical profile in women with polycystic ovarian syndrome attending tertiary care centre of central NEPAL

Rajbanshi¹,

Sharma²,

Tuladhar³

et al. 2023

BMC Women's Health

View full text Add to dashboard Cite

Background Polycystic Ovarian Syndrome (PCOS) is a common endocrinopathy in women of reproductive age group and is highly associated with an increased risk of diabetes, hypertension, cardiovascular disease, and hyper estrogen-related malignancies in women with PCOS. This study was intended to assess the metabolic and hormonal profile of the patients with polycystic ovarian syndrome attending a tertiary care hospital. Methodology A descriptive cross-sectional study was conducted among 107 women diagnosed with polycystic ovarian syndrome from the Department of Clinical Biochemistry of Tribhuvan University and Teaching Hospital. Descriptive analysis was performed to determine the socio-demographic characteristics of the participants. Bivariate analysis was conducted to determine using a t-test for comparing means between two groups and ANOVA for comparing the hormonal and metabolic parameters. Results The mean age of the participants was 27 ± 4 years. This study showed that blood pressure was significantly higher in overweight and obese women (p = 0.001). The obese group had significantly higher serum TSH than the normal group (10.04 vs. 2.73, p = 0.001). Abnormal glucose and hyperinsulinemia were present in 4% of the patients, while 40% had Vitamin D deficiency. Hypothyroidism (TSH ≥ 4.5 mIU/ml) was found in 11% of the PCOS participants with a mean value of 6.65 ± 21.17 mIU/ml. Hyperprolactinemia ≥ 26.8 ng/ml was depicted in 21% of the study population with a mean value of 37.25 ± 21.86 ng/ml. Conclusion Our study demonstrated that PCOS is most commonly prevalent in young women of the reproductive age group which can lead to reproductive, metabolic, and oncological complications in the long term. LH/ FSH ratio was found to be significantly deranged indicating that PCOS should be diagnosed and treated early in the adolescent age group.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic and biochemical profile in women with polycystic ovarian syndrome attending tertiary care centre of central NEPAL

Rajbanshi¹,

Sharma²,

Tuladhar³

et al. 2023

BMC Women's Health

View full text Add to dashboard Cite

show abstract

“…48 Supporting these findings, a very recent study including a subcohort of 512 normal-weight women with PCOS (BMI < 25 kg/m 2 ) and 281 age-and BMI-matched controls from a Nordic cross-sectional base, reported that HTN was more common in PCOS subjects; however, after the age of 35 years, the prevalence of HTN was comparable in women with PCOS and controls. 49 Overall, available data suggest that increased risk of HTN in women with PCOS ameliorates with ageing and is similar to that of controls after menopause.…”

Section: Hypertensionmentioning

confidence: 94%

The impact of ageing and menopause in women with polycystic ovary syndrome

Helvacı

Yildiz

2021

Clinical Endocrinology

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a common hormonal, metabolic and reproductive disorder. Women with PCOS at reproductive age have increased risk and prevalence of prediabetes and diabetes and have multiple risk factors for cardiometabolic disease and other comorbidities such as obstructive sleep apnoea, endometrial cancer and mood disorders, which contribute to the overall health burden of the syndrome. However, little is known about the impact of PCOS on long‐term health in ageing women. In this review, we aimed to give an updated overview regarding the long‐term health outcomes of PCOS and their clinical implications in peri‐ and postmenopause. The PCOS phenotype ameliorates with ageing and limited available data suggest that there is no further deterioration in cardiometabolic profile in women with PCOS after menopause. Accordingly, the risk of cardiovascular disease in ageing women with PCOS seems to be no different from those without PCOS and lower than previously anticipated based on their risk during reproductive years. Regarding other comorbidities including sleep apnoea, mood disorders and endometrial cancer, it is difficult to determine the true risk in older women with PCOS due to the confounding factors and lack of long‐term cohort studies. Large, prospective studies on community‐based and well‐phenotyped PCOS cohorts with extended follow‐up into late menopause are needed to confirm these findings.

show abstract

“…Moreover, blood pressure could be only mildly elevated as demonstrated in 24-hour ambulatory blood pressure measurements in women with PCOS ( 75 ). Obesity is associated with hypertension, but women with PCOS, even with normal weight, can have elevated blood pressure ( 76 ). The specific mechanism(s) that lead to elevated blood pressure or hypertension in PCOS remain a matter of debate.…”

Section: Hypertension and Sglt2 Inhibition In Pcosmentioning

confidence: 99%

Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors

Pruett

Romero²,

Cardozo³

2023

Front. Endocrinol.

View full text Add to dashboard Cite

Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS is characterized by androgen excess, oligo/anovulation, and polycystic appearance of the ovaries. Women with PCOS have an increased prevalence of multiple cardiovascular risk factors such as insulin resistance, hypertension, renal injury, and obesity. Unfortunately, there is a lack of effective, evidence-based pharmacotherapeutics to target these cardiometabolic complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular protection in patients with and without type 2 diabetes mellitus. Although the exact mechanisms of how SGLT2 inhibitors confer cardiovascular protection remains unclear, numerous mechanistic hypotheses for this protection include modulation of the renin-angiotensin system and/or the sympathetic nervous system and improvement in mitochondrial function. Data from recent clinical trials and basic research show a potential role for SGLT2 inhibitors in treating obesity-associated cardiometabolic complications in PCOS. This narrative review discusses the mechanisms of the beneficial effect of SGLT2 inhibitors in cardiometabolic diseases in PCOS.

show abstract

Higher blood pressure in normal weight women with PCOS compared to controls

Cited by 19 publications

References 45 publications

Metabolic and biochemical profile in women with polycystic ovarian syndrome attending tertiary care centre of central NEPAL

Metabolic and biochemical profile in women with polycystic ovarian syndrome attending tertiary care centre of central NEPAL

The impact of ageing and menopause in women with polycystic ovary syndrome

Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors

Contact Info

Product

Resources

About